Rayaldee 30 µg, Weichkapseln retardiert

7680676140014 CH-67614 Weichkapseln

Associated product:

RAYALDEE caps moll LP 30 µg 30 pce flacon
Rayaldee 30 µg, Weichkapseln retardiert
Fiches Amavita / Sun Store / Coop Vitality

Article details

Package size
30
Selling units
30
Measure
Kapsel(n)
Galenic form
Weichkapseln
Galenic group
Tabletten

Official Swissmedic V2 data

Additional information from the official database

Official medical documents

Patient information leaflet
Allemand
22/03/2022
Patient information leaflet
Français
22/03/2022
Patient information leaflet
Italien
22/03/2022
Summary of Product Characteristics
Allemand
22/03/2022
Summary of Product Characteristics
Français
22/03/2022
Summary of Product Characteristics
Italien
22/03/2022

Detailed composition

Substance Quantity Type Category
calcifediolum
30.0 UG Substance Wirkstoff (Principe actif)
calcifediolum monohydricum
- Substance WIZUS
paraffinum solidum
- Substance HNIDK
paraffinum liquidum
- Substance HNIDK
hypromellosum
- Substance HNIDK
glyceroli monostearas 40-55
- Substance HNIDK
macrogolglyceridorum laurates
- Substance HNIDK
ethanolum anhydricum
3.944 MG Substance HBESI
E 321
- Substance ANTOX
amylum hydroxypropylum
- Substance HNIDK
carrageenanum
- Substance HNIDK
sorbitolum liquidum partim deshydricum
- Substance HNIDK
sorbitolum
18.0 MG Substance HBESI
dinatrii phosphas
- Substance HNIDK
natrium
0.3 MG Substance HBESI
titanii dioxidum
- Substance HNIDK
E 133
- Substance FIMDK
aqua purificata
- Substance HNIDK

Reimbursement information

Public price
CHF 112.30
Specialties list
Yes
Generic
No

Reimbursement limitation

SL addition date: 01/03/2022

Authorization holder

Vifor Fresenius Medical Care

9014 St. Gallen

Authorization information

Swissmedic authorization number
67614
Drug name
Rayaldee, Weichkapseln retardiert
Galenic form
KAPS
ATC Code
H05BX05
Authorization status
Z
Dispensing category
B
First authorization
22/12/2020
Authorization expiration date
31/12/9999
IT Number
07.02.3.
Domain
Human medicine
Field of application
Rayaldee ist zur Behandlung von sekundärem Hyperparathyreoidismus (SHPT) bei Erwachsenen mit chronischer Niereninsuffizienz (CKD) im Stadium 3 oder 4 und 25- Hydroxyvitamin-D-Serumwerten <30 ng/ml indiziert.

Package details

Description (FR)
RAYALDEE caps moll 30 mcg bte 30 pce
Description (DE)
RAYALDEE Weichkaps 30 mcg Ds 30 Stk
Market launch
22/12/2020
Narcotic (BTM)
No
Buy us a coffee Explore the data